Studies have shown that Prolia® (denosumab) effectively lowers vertebral fracture risk in male osteoporosis
For the treatment of osteoporosis in men, Prolia® (denosumab) has been compared with placebo in one main study involving 242 men with osteoporosis. The primary endpoint was the change in bone density in the lumbar spine. Prolia® (denosumab) has also been studied in 1,468 men receiving treatment for prostate cancer who were at an increased risk of fracture. Efficacy was clearly demonstrated. Despite a higher average body weight in men compared to women (mean 85.2 vs. 69.8 kg), no notable differences in exposure have been noted.